Your browser doesn't support javascript.
loading
[The rational use of anti-vascular endothelial growth factor drugs to assist the treatment of diabetic retinopathy].
Zhao, M W; Sun, Y Y; Xu, X.
Afiliación
  • Zhao MW; Department of Ophthalmology, Peking University People's Hospital, Eye diseases and optometry institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China.
  • Sun YY; Department of Ophthalmology, Peking University People's Hospital, Eye diseases and optometry institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, Beijing 100044, China.
  • Xu X; Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Eye Disease Prevention and Treatment Center, Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai 200080, China.
Zhonghua Yan Ke Za Zhi ; 55(8): 565-568, 2019 Aug 11.
Article en Zh | MEDLINE | ID: mdl-31422634
Diabetic retinopathy (DR) is one of the most important etiologies of diabetic blindness. The vascular endothelial growth factor (VEGF) is thought to mediate pathophysiological changes of DR. Anti-VEGF therapy for DRdevelops rapidly. However, there are some misunderstandings about its clinical application, and the strategy is not clear. Sometimes its therapeutic effects are even exaggerated. In this article, by discussing whether anti-VEGF therapy can reverse the course of DR disease, promote the absorption of vitreous hemorrhage, and replace fundus laser therapy, the application strategy of anti-VEGF therapy for DR is proposed. At present, anti-VEGF therapy cannot completely replace retinal photocoagulation therapy, and its clinical application value should not be exaggerated. More innovative drugs and therapies are expected to provide new ways forthe treatment of DR while preserving visual function. (Chin J Ophthalmol, 2019, 55: 565-568).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Factor A de Crecimiento Endotelial Vascular / Retinopatía Diabética Límite: Humans Idioma: Zh Revista: Zhonghua Yan Ke Za Zhi Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de la Angiogénesis / Factor A de Crecimiento Endotelial Vascular / Retinopatía Diabética Límite: Humans Idioma: Zh Revista: Zhonghua Yan Ke Za Zhi Año: 2019 Tipo del documento: Article País de afiliación: China Pais de publicación: China